Maximum quantity allowed is 999
请选择数量
CAS RN: 162011-90-7 | 產品號碼: R0206
產品號碼 | R0206 |
純度/分析方法 | >98.0%(GC) |
分子式 / 分子量 | C__1__7H__1__4O__4S = 314.36 |
外觀與形狀(20°C) | Solid |
儲存條件 | Room Temperature (Recommended in a cool and dark place, <15°C) |
包裝和容器 | 250MG-Glass Bottle with Plastic Insert (閲覽圖片) |
CAS RN | 162011-90-7 |
Reaxys-RN | 8269007 |
PubChem Substance ID | 354335586 |
Merck Index(14) | 8248 |
MDL編號 | MFCD00935806 |
產品規格
Appearance | White to Yellow to Orange powder to crystal |
Purity(GC) | min. 98.0 % |
Melting point | 207.0 to 211.0 °C |
NMR | confirm to structure |
性質
熔點 | 209 °C |
水溶性 | Insoluble |
Degree of solubility in water | 472 mg/l 25 °C |
溶解性(微溶於) | Methanol |
GHS
圖形表示 |
![]() |
信號詞 | Warning |
危險性說明 | H302 : Harmful if swallowed. |
防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
相關法規
RTECS # | LU5135000 |
運輸資料
HS編碼* | 2932.20-000 |
Application
Rofecoxib: A Selective Cyclooxygenase-2 (COX-2) Inhibitor
Rofecoxib is a non-steroidal anti-inflammatory drug (NSAID), and a selective cyclooxygenase-2 (COX-2) inhibitor. The mechanism of action is mainly by inhibition of the enzyme COX in the arachidonic acid metabolism pathway, resulting in reduced prostaglandin synthesis. In theory, a drug that selectively inhibited COX-2 might block inflammation, pain, and fever produced by prostaglandins while reducing the side effects (gastric erosions and ulcers) associated with inhibition of COX-1. For your reference, rofecoxib was withdrawn from the medicine market in 2004 after it was shown that long-term clinical use could increase the risk of heart attack and stroke. (The product is for research purpose only.)
References
- The discovery of rofecoxib, [MK 966, Vioxx®, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
- Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
- Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
- Progress in COX-2 inhibitors: a journey so far (a review)
- Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection
- Review of the applications of different analytical techniques for coxibs research (a review)
考研文獻
文檔
產品介紹報導
產品文件 (部分產品的分析圖譜無法提供,敬請諒解。)
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助,請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注:該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉,您搜索的分析圖譜無法提供。